Illumina Inc (ILMN)

$100.11 +0.14 (0.14%)
Market Cap 15.37B
Revenue (ttm) 4.37B
Net Income (ttm) -1.22B
EPS (ttm) N/A
PE Ratio 23.37
Forward PE 21.66
Profit Margin -27.97%
Debt to Equity Ratio 0.66
Volume 948,700
Avg Vol 1,530,780
Day's Range N/A - N/A
Shares Out 153.70M
Stochastic %K 85%
Beta 1.40
Analysts Sell
Price Target $110.48

Company Profile

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other g...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 858 202 4500
Fax: 858 202 4545
Address:
5200 Illumina Way, San Diego, United States
dopeles
dopeles Oct. 24 at 1:43 PM
$PACB we gonna be alright! $ILMN Meanwhile show some love to $VXRT leader in pill vaccine research
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Oct. 24 at 1:34 PM
$ILMN RSI: 51.47, MACD: 0.3321 Vol: 3.39, MA20: 97.22, MA50: 98.21 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
angelinvesting369
angelinvesting369 Oct. 23 at 12:35 PM
$TSLA Like Tesla $ILMN Illumina has done some amazing things. They created gene sequencing. They also created $GRAL . Their only mistake was spinning Grail off. The reason they paid so much $8B in their failed attempt to buy Grail back is they knew Grail has an almost infinite TAM. https://youtu.be/j16zw6v5nQ4?si=LYINZL6MX4A49J2X
0 · Reply
dopeles
dopeles Oct. 23 at 2:34 AM
$PACB something big is coming, I can feel it in the air 😉 $ILMN
2 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 21 at 6:09 PM
$ILMN $TXG
0 · Reply
Jabrontinoooooooo
Jabrontinoooooooo Oct. 21 at 4:46 PM
$ILMN adding
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 21 at 2:54 PM
Enter: $ILMN NOV 21 2025 $100 CALLS Buy in Price: $6.69 - $7.02 Take Profit: $11.37 Stop Bleeding: $5.89 ROI Potential: 70% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
Opposite_George_banned
Opposite_George_banned Oct. 21 at 1:23 PM
$PACB disrupting an established industry with well known names like $ILMN and $TMO is not gonna be easy but hey, if you can get better results with less money why wouldn't PacBio become the leader in the field?
1 · Reply
MoneyMach
MoneyMach Oct. 20 at 5:32 PM
$PACB showing real momentum as its long-read sequencing tech gains traction with new genome project collaborations and expanding partnerships. With giants like $ILMN and $TMO leading the biotech landscape, PacBio stands out as the underdog quietly catching up with disruptive precision. If this innovation cycle holds, $PACB could turn into the most underestimated growth story in genomics .. the calm before a big biotech wave. 🧬
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 20 at 3:46 PM
Enter: $ILMN NOV 21 2025 $100 CALLS Buy in Price: $5.08 - $5.60 Take Profit: $9.14 Stop Bleeding: $4.47 ROI Potential: 80% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
Latest News on ILMN
Illumina: Innovation Outweighs Short-Term Risks - A Long-Term Buy Ahead Of Q3 Earnings

Oct 21, 2025, 2:16 PM EDT - 4 days ago

Illumina: Innovation Outweighs Short-Term Risks - A Long-Term Buy Ahead Of Q3 Earnings

Final Trades: Illumina, Columbia Banking, Alibaba and JPMorgan Chase

Oct 20, 2025, 4:21 PM EDT - 4 days ago

Final Trades: Illumina, Columbia Banking, Alibaba and JPMorgan Chase

BABA COLB JPM

Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights

Oct 15, 2025, 9:15 AM EDT - 10 days ago

Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights

Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot

Oct 15, 2025, 9:15 AM EDT - 10 days ago

Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot

WGS

Illumina to Announce Third Quarter 2025 Financial Results on Thursday, October 30, 2025

Oct 14, 2025, 4:05 PM EDT - 10 days ago

Illumina to Announce Third Quarter 2025 Financial Results on Thursday, October 30, 2025

Illumina launches new business to accelerate technology and data-driven discovery

Oct 1, 2025, 9:05 AM EDT - 24 days ago

Illumina launches new business to accelerate technology and data-driven discovery

ILMN Stock vs. IQV Stock

Sep 26, 2025, 9:40 AM EDT - 4 weeks ago

ILMN Stock vs. IQV Stock

IQV

Illumina advances personalized cancer care with new pharma development partnerships

Sep 23, 2025, 9:15 AM EDT - 4 weeks ago

Illumina advances personalized cancer care with new pharma development partnerships

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

Sep 18, 2025, 9:15 AM EDT - 5 weeks ago

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

ALNY

Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development

Sep 3, 2025, 9:15 AM EDT - 7 weeks ago

Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development

LAB

mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 2 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR GRAL IONS MRNA RGEN

Illumina: The Stock Is Still Undervalued

Aug 4, 2025, 4:23 AM EDT - 2 months ago

Illumina: The Stock Is Still Undervalued

These Analysts Boost Their Forecasts On Illumina Following Upbeat Results

Aug 1, 2025, 12:02 PM EDT - 3 months ago

These Analysts Boost Their Forecasts On Illumina Following Upbeat Results

Illumina, Inc. (ILMN) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 1:25 AM EDT - 3 months ago

Illumina, Inc. (ILMN) Q2 2025 Earnings Call Transcript

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025

Jul 31, 2025, 4:05 PM EDT - 3 months ago

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025

Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling

Jul 30, 2025, 9:15 AM EDT - 3 months ago

Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling

Illumina Stock: What Went Wrong And Why It's Best To Stay Away

Jul 17, 2025, 7:45 AM EDT - 3 months ago

Illumina Stock: What Went Wrong And Why It's Best To Stay Away

Illumina: Higher Profit Margin Despite GRAIL Divestiture And Macroeconomic Headwinds

Jul 12, 2025, 3:46 AM EDT - 3 months ago

Illumina: Higher Profit Margin Despite GRAIL Divestiture And Macroeconomic Headwinds

Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025

Jul 10, 2025, 4:05 PM EDT - 3 months ago

Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025

Illumina named to TIME's World's Most Sustainable Companies list for the second consecutive year

Jul 10, 2025, 9:15 AM EDT - 3 months ago

Illumina named to TIME's World's Most Sustainable Companies list for the second consecutive year

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

Jun 23, 2025, 7:13 AM EDT - 4 months ago

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

LAB

Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling

Jun 18, 2025, 9:00 AM EDT - 4 months ago

Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling

lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics

Jun 10, 2025, 4:01 PM EDT - 4 months ago

lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics

Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis

May 29, 2025, 2:01 PM EDT - 5 months ago

Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis

Illumina, Inc. (ILMN) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

May 29, 2025, 12:18 AM EDT - 5 months ago

Illumina, Inc. (ILMN) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

May 28, 2025, 12:22 PM EDT - 5 months ago

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

AMGN BIIB DHR GILD IBB NVS SDGR

Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies

May 28, 2025, 9:15 AM EDT - 5 months ago

Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies

Signios Bio and Illumina Announce Grant to Maximize Discovery Power with Industry's Largest NGS-Based Proteomics Panel

May 19, 2025, 11:47 AM EDT - 5 months ago

Signios Bio and Illumina Announce Grant to Maximize Discovery Power with Industry's Largest NGS-Based Proteomics Panel

Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%

May 16, 2025, 11:28 AM EDT - 5 months ago

Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%

JBLU

Illumina To Webcast Upcoming Investor Conference

May 14, 2025, 4:05 PM EDT - 5 months ago

Illumina To Webcast Upcoming Investor Conference

Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications

May 13, 2025, 9:15 AM EDT - 5 months ago

Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications

Illumina Analysts Lower Their Forecasts After Q1 Results

May 12, 2025, 11:28 AM EDT - 5 months ago

Illumina Analysts Lower Their Forecasts After Q1 Results

Illumina: Multiple Headwinds Point To Limited Upside In 2025

May 10, 2025, 10:58 PM EDT - 5 months ago

Illumina: Multiple Headwinds Point To Limited Upside In 2025

Illumina, Inc. (ILMN) Q1 2025 Earnings Call Transcript

May 8, 2025, 9:01 PM EDT - 6 months ago

Illumina, Inc. (ILMN) Q1 2025 Earnings Call Transcript

Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development

May 1, 2025, 9:15 AM EDT - 6 months ago

Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development

Target Validation for Genetic Targets Innovation Research Report 2025: 14,172 Deals Totaling $11.4 Billion - BGI biotech and illumina are Among the Leaders with Strong Portfolios

Apr 18, 2025, 10:25 AM EDT - 6 months ago

Target Validation for Genetic Targets Innovation Research Report 2025: 14,172 Deals Totaling $11.4 Billion - BGI biotech and illumina are Among the Leaders with Strong Portfolios

Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation

Apr 15, 2025, 9:15 AM EDT - 6 months ago

Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation

TEM

Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025

Apr 10, 2025, 4:05 PM EDT - 7 months ago

Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025

Corvex's Meister joins the board at Illumina. Here's how he can create value for shareholders

Mar 29, 2025, 7:25 AM EDT - 7 months ago

Corvex's Meister joins the board at Illumina. Here's how he can create value for shareholders

Is Illumina Undervalued After An 83% Drop In Its Stock Price?

Mar 27, 2025, 8:35 AM EDT - 7 months ago

Is Illumina Undervalued After An 83% Drop In Its Stock Price?

Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors

Mar 25, 2025, 9:00 AM EDT - 7 months ago

Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors

Activist investor Keith Meister to join Illumina's board, WSJ reports

Mar 25, 2025, 8:18 AM EDT - 7 months ago

Activist investor Keith Meister to join Illumina's board, WSJ reports

Activist Investor Meister to Join Illumina's Board

Mar 25, 2025, 8:00 AM EDT - 7 months ago

Activist Investor Meister to Join Illumina's Board

Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery

Mar 19, 2025, 9:15 AM EDT - 7 months ago

Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery

Illumina lowers outlook due to China sales ban, to cut $100 million in costs

Mar 10, 2025, 4:22 PM EDT - 8 months ago

Illumina lowers outlook due to China sales ban, to cut $100 million in costs

Illumina addresses recent developments in China

Mar 10, 2025, 4:10 PM EDT - 8 months ago

Illumina addresses recent developments in China

Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban

Mar 10, 2025, 4:01 PM EDT - 8 months ago

Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban

Illumina named to Dow Jones Best-in-Class Indices for sixth consecutive year and as a Sustainability Yearbook Member for fourth consecutive year

Mar 6, 2025, 9:15 AM EST - 8 months ago

Illumina named to Dow Jones Best-in-Class Indices for sixth consecutive year and as a Sustainability Yearbook Member for fourth consecutive year

US Firm Illumina Faces Setback as China Blocks Imports Amid Escalating Trade War

Mar 4, 2025, 9:57 AM EST - 8 months ago

US Firm Illumina Faces Setback as China Blocks Imports Amid Escalating Trade War

Illumina Stock Drops as China Bans Imports of Gene-Sequencing Technology

Mar 4, 2025, 9:38 AM EST - 8 months ago

Illumina Stock Drops as China Bans Imports of Gene-Sequencing Technology

dopeles
dopeles Oct. 24 at 1:43 PM
$PACB we gonna be alright! $ILMN Meanwhile show some love to $VXRT leader in pill vaccine research
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Oct. 24 at 1:34 PM
$ILMN RSI: 51.47, MACD: 0.3321 Vol: 3.39, MA20: 97.22, MA50: 98.21 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
angelinvesting369
angelinvesting369 Oct. 23 at 12:35 PM
$TSLA Like Tesla $ILMN Illumina has done some amazing things. They created gene sequencing. They also created $GRAL . Their only mistake was spinning Grail off. The reason they paid so much $8B in their failed attempt to buy Grail back is they knew Grail has an almost infinite TAM. https://youtu.be/j16zw6v5nQ4?si=LYINZL6MX4A49J2X
0 · Reply
dopeles
dopeles Oct. 23 at 2:34 AM
$PACB something big is coming, I can feel it in the air 😉 $ILMN
2 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 21 at 6:09 PM
$ILMN $TXG
0 · Reply
Jabrontinoooooooo
Jabrontinoooooooo Oct. 21 at 4:46 PM
$ILMN adding
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 21 at 2:54 PM
Enter: $ILMN NOV 21 2025 $100 CALLS Buy in Price: $6.69 - $7.02 Take Profit: $11.37 Stop Bleeding: $5.89 ROI Potential: 70% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
Opposite_George_banned
Opposite_George_banned Oct. 21 at 1:23 PM
$PACB disrupting an established industry with well known names like $ILMN and $TMO is not gonna be easy but hey, if you can get better results with less money why wouldn't PacBio become the leader in the field?
1 · Reply
MoneyMach
MoneyMach Oct. 20 at 5:32 PM
$PACB showing real momentum as its long-read sequencing tech gains traction with new genome project collaborations and expanding partnerships. With giants like $ILMN and $TMO leading the biotech landscape, PacBio stands out as the underdog quietly catching up with disruptive precision. If this innovation cycle holds, $PACB could turn into the most underestimated growth story in genomics .. the calm before a big biotech wave. 🧬
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 20 at 3:46 PM
Enter: $ILMN NOV 21 2025 $100 CALLS Buy in Price: $5.08 - $5.60 Take Profit: $9.14 Stop Bleeding: $4.47 ROI Potential: 80% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
tievLeaf
tievLeaf Oct. 19 at 10:59 AM
$QSI WHAT ARE EVERYONE THOUGHTS FOR THIS WEEK? ANY PRICE RANGE? I STILL THINK THIS REDDIT POST IS CRAZY https://www.reddit.com/r/pennystocks/comments/1o9o1ze/quantumsi_qsi_and_evidence_of_why_nvidia_is_the/ AND IT IS GAINING SO MUCH TRACTION!! $NVDA $RXRX $RGTI $ILMN
1 · Reply
cimaboy
cimaboy Oct. 18 at 12:58 PM
$QSI $NVDA $ILMN $RXRX $RGTI 😍😍😍😍😍😍😍😍
1 · Reply
tievLeaf
tievLeaf Oct. 18 at 7:07 AM
$QSI This is a fucking great write-up. READ THIS FOR FUCK SAFE. $NVDA $ILMN $RXRX $RGTI https://www.reddit.com/r/pennystocks/comments/1o9o1ze/quantumsi_qsi_and_evidence_of_why_nvidia_is_the/
2 · Reply
tievLeaf
tievLeaf Oct. 18 at 6:09 AM
$QSI EVERYONE SHOULD READ THIS POST ABOUT QUANTUM SI AND NVIDIA !! $NVDA $ILMN $RGTI https://www.reddit.com/r/pennystocks/comments/1o9o1ze/quantumsi_qsi_and_evidence_of_why_nvidia_is_the/
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 17 at 4:40 AM
Enter: $ILMN NOV 21 2025 $95 CALLS Buy in Price: $6.70 - $7.00 Take Profit: $8.91 Stop Bleeding: $5.90 ROI Potential: 33% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
rodeoraman
rodeoraman Oct. 16 at 10:15 PM
$ILMN Is Illumina working with openAI ?
1 · Reply
tievLeaf
tievLeaf Oct. 16 at 6:18 PM
$QSI 41.95million trade volume on this small biotech stock wtf lol $NVDA $ILMN $CCCX $HOND
0 · Reply
tievLeaf
tievLeaf Oct. 16 at 5:16 PM
$QSI this may actually go to $10 in november. wtf $NVDA $ILMN $RGTI $CCCX
1 · Reply
tarzzanman
tarzzanman Oct. 14 at 4:52 PM
$ILMN Worst of the worst to hold 🤢
0 · Reply
TheMicronBull
TheMicronBull Oct. 14 at 2:33 PM
$ILMN broke support level alerts by market.page/alerts
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 14 at 4:04 AM
$ILMN Share Price: $95.01 Contract Selected: Jan 16, 2026 $95 Calls Buy Zone: $7.39 – $9.13 Target Zone: $12.41 – $15.17 Potential Upside: 59% ROI Time to Expiration: 94 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
patten1962
patten1962 Oct. 14 at 3:44 AM
$PACB Could be buyout talks? $ILMN was interested years ago and CEO, Christian Henry did work for them. Oh, so did COO, Mark Van Oene ! Maybe its $A or $TMO ? Or maybe is up 17% for no reason with 13m shares traded and large institutional ownership? Time will tell.
0 · Reply